BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6567645)

  • 1. Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.
    Lambris JD; Müller-Eberhard HJ
    J Biol Chem; 1984 Oct; 259(20):12685-90. PubMed ID: 6567645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymerization of factor B of the alternative complement pathway via disulfide bond(s) in the presence of Cu2+ and stimulation by C3b, the major fragment of C3.
    Matsushita M; Iwasaki A; Okada H
    Biochem Biophys Res Commun; 1989 Nov; 165(1):101-5. PubMed ID: 2590211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
    Pryzdial EL; Isenman DE
    J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.
    Maillet F; Kazatchkine MD; Glotz D; Fischer E; Rowe M
    Mol Immunol; 1983 Dec; 20(12):1401-4. PubMed ID: 6558419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the binding molecules for factor B and its fragment, Bb, of human complement on human monocytes after in vitro cultivation.
    Saeki T; Nagasawa S
    Immunol Lett; 1989 Jan; 20(2):97-101. PubMed ID: 2654014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. A possible role for C5 in monocyte spreading.
    Sundsmo JS; Götze O
    J Exp Med; 1981 Sep; 154(3):763-77. PubMed ID: 6912276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing functional sites on complement protein B with monoclonal antibodies. Evidence for C3b-binding sites on Ba.
    Ueda A; Kearney JF; Roux KH; Volanakis JE
    J Immunol; 1987 Feb; 138(4):1143-9. PubMed ID: 2433342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
    Koistinen V; Wessberg S; Leikola J
    Complement Inflamm; 1989; 6(4):270-80. PubMed ID: 2527715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples.
    Kolb WP; Morrow PR; Tamerius JD
    Complement Inflamm; 1989; 6(3):175-204. PubMed ID: 2472921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding.
    Hourcade DE; Mitchell LM; Oglesby TJ
    J Immunol; 1999 Mar; 162(5):2906-11. PubMed ID: 10072540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement 1 inhibitor is a regulator of the alternative complement pathway.
    Jiang H; Wagner E; Zhang H; Frank MM
    J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b.
    Kozono H; Kinoshita T; Kim YU; Takata-Kozono Y; Tsunasawa S; Sakiyama F; Takeda J; Hong K; Inoue K
    J Biol Chem; 1990 Aug; 265(24):14444-9. PubMed ID: 2387864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
    Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
    J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.